Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Immupharma Share News (IMM)
IMM Share
Price
IMM Share
News
IMM Share
Chat
IMM Share
Trades
IMM
Live RNS
IMM Share
Charts
IMM Level 2
Console
IMM Live
Share Price
IMM Broker
Ratings
IMM Directors
Deals
IMM Financial
Diary
IMM
Fundamentals
IMM Short
Positions
IMM
Media
IMM Company
Research
IMM Company
Timeline
Share Price Information for Immupharma (IMM)
Last checked at -
Last checked at 
Intraday Immupharma Share Chart
Immupharma News
Immupharma to make 'blockbuster' lupus treatment available
(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lup...
Immupharma Says P140 Peptide Shows Positive Results In CIDP Treatment
LONDON (Alliance News) - ImmuPharma PLC said Thursday that its pre-clinical studies of the P140 peptide showed positive results in the treatment of ch...
ImmuPharma Excited Despite Widened Loss As Lupuzor Makes Good Results
LONDON (Alliance News) - ImmuPharma PLC said Tuesday it continues to be "excited" by its future potential despite a widened loss for 2017.The drug dev...
ImmuPharma Prepares To Report Lupuzor Study Results In April
LONDON (Alliance News) - Drug development company ImmuPharma PLC said on Friday it has been informed by Simbec-Orion that the data-base lock for the L...
ImmuPharma trial of Lupuzor continuing smoothly
(ShareCast News) - Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, follow...
ImmuPharma completes patient recruitment in Lupuzor trial
(ShareCast News) - Specialist drug discovery and development company ImmuPharma confirmed on Thursday that patient recruitment had successfully been c...
ImmuPharma makes positive progress in Lupuzor trials
(ShareCast News) - Specialist drug discovery and development company ImmuPharma updated the market on the progress of its Phase III clinical trial of ...
Follow the stocks
